Brian Druker

Professor

  • 67169 Citations
  • 111 h-Index
1981 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Letter
2019

Reply to n. Cerveira et al

Berman, E., Druker, B. J. & Burwick, R., Jan 1 2019, In : Journal of Clinical Oncology. 37, 1, 1 p.

Research output: Contribution to journalLetter

2018

Automated decision tree to evaluate genetic abnormalities when determining prognostic risk in acute myeloid leukemia

Watanabe-Smith, K., Druker, B. J., Tyner, J. W. & Edwards, D. K., Jul 31 2018, In : Haematologica. 103, 8, p. e351-e355

Research output: Contribution to journalLetter

1 Scopus citations

Reply to D.M. Ross et al and V. Florou et al

Berman, E., Druker, B. J. & Burwick, R., Sep 1 2018, In : Journal of Clinical Oncology. 36, 25, p. 2660-2661 2 p.

Research output: Contribution to journalLetter

Recurrent cyclin D2 mutations in myeloid neoplasms

Khanna, V., Eide, C. A., Tognon, C. E., Maxson, J., Wilmot, B., Bottomly, D., McWeeney, S., Edwards, V. D. K., Druker, B. & Tyner, J., Sep 1 2017, In : Leukemia. 31, 9, p. 2005-2008 4 p.

Research output: Contribution to journalLetter

3 Scopus citations
2016

Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia

Watanabe-Smith, K., Tognon, C., Tyner, J., Meijerink, J. P. P., Druker, B. & Agarwal, A., Sep 1 2016, In : Leukemia. 30, 9, p. 1950-1953 4 p.

Research output: Contribution to journalLetter

7 Scopus citations
2012

Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors

Traer, E., MacKenzie, R., Snead, J., Agarwal, A., Eiring, A. M., O'Hare, T., Druker, B. J. & Deininger, M. W., May 2012, In : Leukemia. 26, 5, p. 1140-1143 4 p.

Research output: Contribution to journalLetter

70 Scopus citations

Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL: A Children's Oncology Group (COG) study

Chang, B. H., Willis, S. G., Stork, L., Hunger, S. P., Carroll, W. L., Camitta, B. M., Winick, N. J., Druker, B. J. & Schultz, K. R., May 1 2012, In : British Journal of Haematology. 157, 4, p. 507-510 4 p.

Research output: Contribution to journalLetter

24 Scopus citations
2010

Clonal chromosomal abnormalities in CD34+/CD-38 hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors

Bumm, T., Deininger, J., Newell, A. H., Lawce, H., Olson, S., Mauro, M., Druker, B. & Deininger, M., Aug 2010, In : Leukemia. 24, 8, p. 1525-1528 4 p.

Research output: Contribution to journalLetter

6 Scopus citations

The function of the pleckstrin homology domain in BCR-ABL-mediated leukemogenesis

Demehri, S., O'Hare, T., Eide, C. A., Smith, C. A., Tyner, J. W., Druker, B. J. & Deininger, M. W. N., Jan 2010, In : Leukemia. 24, 1, p. 226-229 4 p.

Research output: Contribution to journalLetter

11 Scopus citations
2009

Functional characterization of an activating TEK mutation in acute myeloid leukemia: A cellular context-dependent activating mutation

Tyner, J. W., Rutenberg-Schoenberg, M. L., Erickson, H., Willis, S. G., O'Hare, T., Deininger, M. W., Druker, B. J. & Loriaux, M. M., Jan 1 2009, In : Leukemia. 23, 7, p. 1345-1348 4 p.

Research output: Contribution to journalLetter

4 Scopus citations

High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia

Tyner, J. W., Loriaux, M. M., Erickson, H., Eide, C. A., Deininger, J., MacPartlin, M., Willis, S. G., Lange, T., Druker, B. J., Kovacsovics, T., Maziarz, R., Gattermann, N. & Deininger, M. W., Jan 1 2009, In : Leukemia. 23, 2, p. 406-409 4 p.

Research output: Contribution to journalLetter

9 Scopus citations
2008

An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia

Agarwal, A., Eide, C. A., Harlow, A., Corbin, A. S., Mauro, M. J., Druker, B. J., Corless, C. L., Heinrich, M. C. & Deininger, M. W., Jan 1 2008, In : Leukemia. 22, 12, p. 2269-2272 4 p.

Research output: Contribution to journalLetter

24 Scopus citations
2007

The authors reply [4]

Druker, B. & Gathmann, I., Apr 26 2007, In : New England Journal of Medicine. 356, 17, 1 p.

Research output: Contribution to journalLetter

2 Scopus citations

Therapeutic drug monitoring in CML patients on imatinib [3]

Blasdel, C., Egorin, M. J., Lagattuta, T. F., Druker, B. J. & Deininger, M. W., Sep 1 2007, In : Blood. 110, 5, p. 1699-1701 3 p.

Research output: Contribution to journalLetter

25 Scopus citations
2005

BIRB-796 is not an effective ABL(T315I) inhibitor [1] (multiple letters)

O'Hare, T., Druker, B. J., Fabian, M. A., Biggs, W. H., Treiber, D. K., Zarrinkar, P. P. & Lockhart, D. J., Oct 1 2005, In : Nature biotechnology. 23, 10, p. 1209-1211 3 p.

Research output: Contribution to journalLetter

15 Scopus citations

e8a2 BCR-ABL: More frequent than other atypical BCR-ABL variants? [5]

Demehri, S., Paschka, P., Schultheis, B., Lange, T., Koizumi, T., Sugimoto, T., Branford, S., Lim, L. C., Kegel, T., Martinelli, G., Hochhaus, A., Druker, B. J. & Deininger, M. W. N., Apr 2005, In : Leukemia. 19, 4, p. 681-684 4 p.

Research output: Contribution to journalLetter

30 Scopus citations

hOCT 1 and resistance to imatinib [1] (multiple letters)

Crossman, L. C., Druker, B. J., Deininger, M. W. N., Pirmohamed, M., Wang, L. & Clark, R. E., Aug 1 2005, In : Blood. 106, 3, p. 1133-1134 2 p.

Research output: Contribution to journalLetter

155 Scopus citations
2003

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels [4] (multiple letters)

Gambacorti-Passerini, C., Piazza, R., D'Incalci, M., Corbin, A., La Rosée, P., Stoffregen, E., Druker, B. & Deininger, M., Sep 1 2003, In : Blood. 102, 5, p. 1933-1935 3 p.

Research output: Contribution to journalLetter

10 Scopus citations
2002

Treatment options in chronic myelogenous leukemia [2] (multiple letters)

Copelan, E. A., Goldman, J. M. & Druker, B. J., Apr 15 2002, In : Blood. 99, 8, p. 3070-3071 2 p.

Research output: Contribution to journalLetter